AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Tezspire (tezepelumab by Quarter
Tezspire (tezepelumab — direct product sales) — Established RoW YoY CER (%) (%)
AstraZeneca Tezspire (tezepelumab: 41.0% in Q2 2026, down 14.0 pts from a year earlier.
Latest, Q2 2026
41.0%
Period ended Jun 30, 2026
Change on a year earlier
-14.0 pts
55.0% in Q2 2025
History
7 quarters
Since Q4 2024
Sources
7
Documents cited below
Where the Q2 2026 figure comes from
“|| Tezspire | | 172 | | 54 | | 51 | | - | | - | | 24 | | n/m | | n/m | | 107 | | 49 | | 42 | | 41 | | 33 | | 41”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tezspire (tezepelumab — direct product sales) — Established RoW YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 41.0% | -14.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 45.0% | -28.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 43.0% | -44.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 43.0% | – | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 55.0% | – | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 73.0% | – | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 87.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Tezspire (tezepelumab (%), quarterly Q4 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tezspire-erow-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.